Browse by category

Medtronic has announced a strategic partnership with Cornerstone Robotics, an innovative surgical robotics company committed to advancing minimally invasive surgery and improving access to the latest surgical care worldwide. The approximately $700 million investment includes rights to distribute Cornerstone Robotics' Sentire surgical system in select markets outside the US where the system is market approved. Cornerstone Robotics' Sentire surgical system Medtronic will distri

Researchers at Pennington Biomedical Research Center, led by Dr Vance Albaugh and lead author of the study, have reported that patients with extreme obesity are more common among those undergoing metabolic and bariatric surgery than previously recognised. However, although they face a greater burden of certain health conditions and surgical complications, their overall surgical risk remains relatively low, according to the study. Figure 1: Credit- PBRC Comorbidity burden of M

Researchers at NYU Abu Dhabi have developed BRIDGE (Biodegradable aRchitected Internal DrainaGE), a biodegradable, 3D-printed gastric stent that could improve treatment for gastric leaks, a serious complication following bariatric surgery. By combining an advanced internal lattice design with biodegradable materials, the new device more than doubles drainage performance while potentially eliminating the need for a second procedure to remove the stent after healing, the resear

According to Professor Ahmed Ahmed, President of the British Obesity and Metabolic Specialist Society, robotic metabolic and bariatric surgery (rMBS) in the UK is still in the early stage of adoption. He said that there are several reasons why the speciality has been slower to adopt this technology compared with other surgical specialities such as urology, thoracic or colorectal. Ahmed Ahmed “I believe one of the reasons is so far there is no clear benefit of rMBS over the mo

Amylyx Pharmaceuticals has announced positive topline results from LUCIDITY, a 78-participant, multi-centre, randomised, double-blind, placebo-controlled Phase 3 clinical trial evaluating the efficacy and safety of avexitide, an investigational, first-in-class glucagon-like peptide-1 (GLP-1) receptor antagonist, in participants with post-bariatric hypoglycemia (PBH) following Roux-en-Y gastric bypass (RYGB) surgery. LUCIDITY met the FDA-agreed-upon primary endpoint demonstrat

An international study led by King’s College London, UK, has found that proposed new obesity definitions give greater insight into the ill health of metabolic bariatric surgery (MBS) candidates, compared with Body Mass Index (BMI). The study, found that people considered for MBS had marked variation in disease burden – the number and severity of diseases – and operation-related risks, despite having similar BMI. However, by reviewing clinical data from thousands of bariatric